Replimune Group

Replimune Group Debt

The Debt of Replimune Group (REPL) as of Oct 14, 2026 is 87.35 M USD. In the previous year, Debt was 71.91 M USD — a change of 21.48% (higher).

Debt

87.35 MUSD

YoY

21.48%

Last updated:

In 2026, Replimune Group's total debt was 87.35 M USD, a 21.48% change from the 71.91 M USD total debt recorded in the previous year.

The Replimune Group Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
6.60 M USD
Jan 1, 2020
37.20 M USD
Jan 1, 2021
27.20 M USD
Jan 1, 2022
27.00 M USD
Jan 1, 2023
55.30 M USD
Jan 1, 2024
70.94 M USD
Jan 1, 2025
71.91 M USD
Jan 1, 2026
87.35 M USD
The Replimune Group Debt history
YEARDebtYoY
87.35 MUSD+21.48%
71.91 MUSD+1.36%
70.94 MUSD+28.28%
55.30 MUSD+104.81%
27.00 MUSD-0.74%
27.20 MUSD-26.88%
37.20 MUSD+463.64%
6.60 MUSD—
0.00USD—
0.00USD—
Access this data via the Eulerpool API
Get Free API Key

Replimune Group Stock analysis

What does Replimune Group do? Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.

Debt Details

Understanding Replimune Group's Debt Structure

Replimune Group's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Replimune Group's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Replimune Group’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Replimune Group’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Replimune Group stock

Debt of Replimune Group is 87.35 M USD in 2026.

Debt of Replimune Group changed from 71.91 M USD to 87.35 M USD, representing a 21.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Replimune Group since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Replimune Group historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Replimune Group

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Replimune Group